Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy (ANKA-PCA)

ATGen

Status: Terminated

Conditions: Prostatic Neoplasm; Immunity, Innate

Treatments: Diagnostic Test: IVDD for NK cell activity in whole blood

Study type: Interventional

Funder types: Industry

Identifiers

NCT03242265

ANKA-PCA

Details and patient eligibility

About

This study will look at measuring the activity of natural killer (NK) cells using the in vitro diagnostic device NK Vue in subjects being screened for prostate cancer using prostate biopsy.

Full description

The NK Vue diagnostic test for natural killer cell activity uses the principle of stimulation of whole blood with a proprietary cytokine followed by the quantitative detection of interferon-gamma using an immunoassay. NK Vue is intended to be used for the monitoring of the immune status of individuals. Measurement of NK cell activity could be a useful tool for assessing changes in immunosurveillance in patients with conditions or diseases where NK cell activity has been shown to be affected.

Enrollment: 84 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Male aged ≥ 18 years old
2. Able to read and sign an approved informed consent form
3. Soon to be undergoing a needle prostate biopsy for suspected prostate cancer; patients with a history of prior biopsy are not excluded provided the biopsy was negative
4. All prior and current recorded PSA levels are < 11 ng/mL (minimum of 2 values must be available)
5. Digital Rectal Exam performed or scheduled to be performed prior to biopsy

Exclusion criteria

1. Any other established malignancy with the exception of basal cell carcinoma

2. At time of blood collection, an active infection (eg bacterial, viral etc.) as declared by the patient

3. Chronic inflammatory condition requiring anti-inflammatory treatment such as rheumatoid arthritis, Crohn's or ulcerative colitis, Lupus or any connective tissue condition which, in the opinion of the investigator, might affect the immune response

4. Presently taking any of the following classes of medications on a regular basis:

   • 5-alpha reductase inhibitors
   • Anti-inflammatories, with the exception of low dose (81 mg) acetylsalicylic acid
   • Anti-androgens
   • Testosterone replacement therapy

Trial design

Primary purpose: Screening

Allocation: N/A

Interventional model: Single Group Assignment

Masking: Single Blind